- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 26, 2023
Discovery & Translation
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Jan 31, 2023
Distillery Therapeutics
Inhibiting excess protein degradtion for fragile X syndrome
BioCentury | Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
BioCentury | Apr 25, 2022
Data Byte
Mechanistic diversity in the pipeline for fragile X syndrome
The fragile X pipeline comprises as many drugs targets as drug candidates
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Mar 25, 2019
Distillery Therapeutics
Two promoters of FMR1 expression to treat Fragile X syndrome
Items per page:
1 - 10 of 37